-
1.发明申请Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers 审中-公开细胞抗原和靶信号转导蛋白的复合谱，用于分析和临床管理血液癌公开(公告)号：US20070105165A1
公开(公告)日：2007-05-10
申请号：US11267948
申请日：2005-11-04
IPC分类号： G01N33/574
CPC分类号： G01N33/57426 , G01N33/5052 , G01N2800/52
摘要： The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
摘要翻译： 本发明涉及用于建立来自疑似具有肿瘤状况的个体的样品的复合标记物谱的方法。 本发明的复合标记物分布允许鉴定预后和治疗相关的肿瘤病症亚组和个体临床病程的预测。 本发明的方法提供了用于选择患有肿瘤病症的个体的治疗的工具，包括分配风险组的方法，预测复发风险增加的方法，预测发生继发性并发症的风险增加的方法，方法 选择个体治疗的方法，确定个体治疗功效的方法以及确定个体预后的方法。 特别地，本发明的方法公开了一种建立复合标记物谱的方法，该方法可用作预后指标以预测个体肿瘤状况的进程是否是侵略性或惰性的，由此帮助临床医师管理 患者和评估使用的治疗方式。 在本文公开的特定实施方案中，本发明的方法涉及建立选自慢性淋巴细胞性白血病（CLL），急性骨髓性白血病（AML），慢性骨髓性白血病（CML）和 急性淋巴细胞性白血病（ALL）。
-
2.发明授权Process of determining the efficacy of drug treatment in HIV infected subjects 失效确定药物治疗在艾滋病毒感染受试者中的功效的过程公开(公告)号：US06210875B1
公开(公告)日：2001-04-03
申请号：US09117076
申请日：1998-07-23
IPC分类号： C12Q170
CPC分类号： C12Q1/703 , C12Q2600/158 , Y10S435/968 , Y10S435/974
摘要： The present invention provides a process for determining the efficacy of anti-viral therapy in an HIV-infected subject receiving such therapy. The process includes the steps of a) detecting the level of transcriptionally active HIV in monocytes of the subject at a plurality of different times, b) comparing the detected HIV levels, and c) correlating changes in the detected HIV levels over time with the therapy. The process can be used to monitor the efficacy of treatment with any anti-HIV agent such as AZT, 3TC, DDC, Indivar, or Saquinavir. Decreases in HIV levels over time indicate an efficacious treatment. Increases in detected HIV levels over time indicate resistance to treatment.
摘要翻译： 本发明提供了在接受这种治疗的HIV感染的受试者中确定抗病毒疗法的功效的方法。 该方法包括以下步骤：a）在多个不同时间检测受试者单核细胞中转录活性的HIV水平; b）比较所检测的HIV水平，和c）将检测到的HIV水平随时间的变化与治疗相关联 。 该过程可用于监测与任何抗HIV药物如AZT，3TC，DDC，靛红或沙奎那韦治疗的疗效。 随着时间的推移，艾滋病毒浓度下降表明有效治疗。 随着时间的推移，检测到的艾滋病毒水平的增加表明抗药性。
-
搜索结果
2 条记录 (耗时 0.017 秒)
